Press Releases
Xencor Closes $50 Million Series C Financing
(BW Healthwire)--July 19, 2001---Xencor today announced that E.William
Radany, Ph.D. has joined the company as Chief Business Officer and
Joyce L. Morrison has joined as Vice President, Intellectual Property.
Each has over 15 years of experience in their field working with life
science companies. Xencor has used the proceeds from its November, 2000
Series C financing to develop a novel platform for the study of
molecular interactions for the generation of new therapeutics and
agricultural products using its proprietary ProCode(tm) technology.
Xencor has also expanded its protein optimization programs using its
Protein Design Automation(tm) (PDA(tm)) technology. The addition of Dr.
Radany and Ms. Morrison will enable Xencor to secure the alliances,
partnerships and intellectual property estate necessary to accelerate
the development and commercialization of its own line of protein-based
products, according to Bassil Dahiyat, Ph.D. President and CEO of
Xencor. “Xencor will clearly benefit from the extensive experience Bill
and Joyce bring to the company,“ Dr. Dahiyat said. “Bill will be in
charge of Xencor's business development efforts, focusing on securing
alliances and partnerships with pharmaceutical, agricultural and
chemical companies for the high-throughput analysis and optimization of
proteins using our ProCode and PDA technologies. Joyce will be
responsible for securing and expanding the patent estate surrounding
these proprietary technologies and the novel compounds Xencor
identifies using them, and will assist in structuring our alliances to
maximize the value of our intellectual property.“ Dr. Radany joins
Xencor from Caliper Technologies Corporation where he was Vice
President, Drug Discovery Program and was successful in the development
and management of corporate alliances with leading pharmaceutical and
biotechnology companies including, Roche, Amgen, Eli Lilly, Millennium
Pharmaceuticals and Sugen. Previously, he was founder and president of
NeoGenex, a developer of reagents for viral diagnostics and held
executive management positions with Stratagene, Biacore and Pharmacia
Biosensor. During his tenure with these companies he was successful in
business development and in turning novel approaches into commercial
products. Dr. Radany received a B.S in Cell Biology from Colorado Sate
University and his Ph.D. in Biochemistry/Physiology from the University
of Wyoming. Ms. Morrison was previously Chief Counsel, Intellectual
Property with Hercules Incorporated, a global leader in the specialty
chemicals market, where she managed and directed worldwide intellectual
property matters including strategic portfolio development and the
transaction and litigation efforts for the company. Prior to joining
Hercules, she was Managing Counsel, Intellectual Property for BASF
Corporation, where she oversaw the IP functions of the life sciences
division, including its agricultural products group and Knoll
Pharmaceutical Company. Her intellectual property experience also
includes work at Centocor, Westinghouse Electric and several years as
Patent Examiner with the United States Patent and Trademark Office. Ms.
Morrison has a B.S. in Chemistry from Grove City College and a J.D.
from the Dickinson School of Law of Pennsylvania State University.
Xencor, a privately held company, is focused on using its cutting edge
protein analysis and optimization technologies to accelerate the
discovery of therapeutic proteins and novel compounds. With its
proprietary ProCode(tm) and Protein Design Automation(tm) (PDA(tm))
technologies, Xencor scientists can rapidly determine the interactions
and functions of a cell's entire protein complement, identify proteins
of interest, and then optimize key properties of these proteins to fit
commercial applications. The use of these technologies alone or in
combination will accelerate the compound identification and development
programs of Xencor's strategic partners in the pharmaceutical,
biotechnology, agricultural and chemical industries. Xencor is
headquartered in Monrovia, California.